SIGA Technologies, Inc. (SIGA) Investor Relations Documents

SIGA Technologies, Inc. (SIGA) investor relations documents from the company's IR site: 1 presentation, 13 press releases; latest deck 2026-05-07. Read in-app with summaries. First-party data.

SIGA’s management presentation: SIGA is a commercial-stage biodefense company whose primary asset, TPOXX, is an FDA-approved antiviral treatment for smallpox with over $680M in recent revenue.

Investor relations documents — source: company IR site
PublishedTypeDocument
2026-08-06Press releaseSIGA Reports Financial Results for Three and Six Months Ended June 30, 2026
2026-08-06Press releasePress Release
2026-07-30Press releaseSIGA to Host Business Update Call on August 6, 2026, Following Release of Second-Quarter 2026 Financial Results
2026-05-07Press releaseSIGA Reports Financial Results for Three Months Ended March 31, 2026 and Provides Business Update
2026-05-07Press releasePress Release of Q1 2026, PDF file, (opens in new window)
2026-05-07PresentationSIGA’s management presentation
2026-04-30Press releaseDownload , SIGA to Host Business Update Call on May 7, 2026, Following Release of First-Quarter 2026 Financial Results,
2026-03-26Press releaseSIGA Declares Special Cash Dividend of $0.60 Per Share
2026-03-10Press releaseSIGA Reports Financial Results for Three and Twelve Months Ended December 31, 2025 and Provides Business Update
2026-03-03Press releaseDownload , SIGA to Host Business Update Call on March 10, 2026, Following Release of 2025 Financial Results, March 3, 20
2025-05-08Press releaseQ1
2025-03-11Press releaseQ4
2024-11-07Press releaseQ3
2024-05-07Press releaseQ1

SIGA overview · SIGA earnings · SIGA financials · SIGA KPIs · SIGA ownership · SIGA peers · SIGA filings

Documents published by the company on its investor-relations site; summaries are model-written. Not personalized investment advice.